Salix Pharmaceuticals Inc
- All
- News
-
Lupin Gets FDA Nod To Market Ulcerative Colitis Tablets, Shares Higher
The company's product is generic version of Salix Pharmaceuticals Inc's Giazo tablets in the same strength, it added.
-
Lupin Launches Anti-Bacterial Zaxine Tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis).
-
Lupin in Deal to Market US Firm Salix's Drugs in Canada
Lupin Ltd, India's fourth-largest drug maker by sales, said it entered into an exclusive deal to market some of US firm Salix Pharmaceuticals Inc's products in Canada to expand its footprint in that region.
-
GLENMARK PHARMACEUTICALS LTD. - Glenmark Pharmaceuticals Limited has received USD 15 million from Salix Pharmaceuticals, Inc, USA
Glenmark Pharmaceuticals Ltd has informed BSE that the Company has received USD 15 million from Salix Pharmaceuticals, Inc, USA. This is as per an Agreement for Advance against Commitment fee which is to cover Glenmark's risks associated with upgrading its manufacturing facilities to meet Salix's anticipated increased requirements in demand...
-
Lupin Gets FDA Nod To Market Ulcerative Colitis Tablets, Shares Higher
The company's product is generic version of Salix Pharmaceuticals Inc's Giazo tablets in the same strength, it added.
-
Lupin Launches Anti-Bacterial Zaxine Tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis).
-
Lupin in Deal to Market US Firm Salix's Drugs in Canada
Lupin Ltd, India's fourth-largest drug maker by sales, said it entered into an exclusive deal to market some of US firm Salix Pharmaceuticals Inc's products in Canada to expand its footprint in that region.
-
GLENMARK PHARMACEUTICALS LTD. - Glenmark Pharmaceuticals Limited has received USD 15 million from Salix Pharmaceuticals, Inc, USA
Glenmark Pharmaceuticals Ltd has informed BSE that the Company has received USD 15 million from Salix Pharmaceuticals, Inc, USA. This is as per an Agreement for Advance against Commitment fee which is to cover Glenmark's risks associated with upgrading its manufacturing facilities to meet Salix's anticipated increased requirements in demand...
